Market Overview

Benzinga's Top Pre-Market Losers

Related RIGL
Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
Earnings Scheduled For March 3, 2015
Related ENDP
Watch Out Below, Endo International Investors, Management Is Doubling Down On Weak Assets
Benzinga's Top Downgrades
The Vetr community has downgraded $ENDP to 4-Stars (Vetr)

Rigel Pharmaceuticals (NASDAQ: RIGL) shares fell 30.96% to $5.82 in the pre-market trading. Rigel Pharmaceuticals' trailing-twelve-month ROE is -45.82%.

Endo Health Solutions (NASDAQ: ENDP) shares dropped 6.38% to $25.84 in pre-market trading. Endo cut its earnings view for 2012 and 2013.

Ciena (NASDAQ: CIEN) dipped 1.73% to $15.30 in the pre-market session. Ciena posted a wider fiscal fourth-quarter loss.

Canadian Solar (NASDAQ: CSIQ) dipped 1.33% to $2.97 in the pre-market session. Canadian Solar named Guangchun Zhang as its Chief Operating Officer.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (CIEN + CSIQ)

Get Benzinga's Newsletters